Rimonabant (Acomplia®) has been launched in the UK. It is licensed as an adjunct to diet and exercise in patients with a BMI > 30kg/m2 or a BMI > 27 kg/m2 and associated risk factors such as Type II Diabetes.
It is expected that there will be a high level of media interest, especially as this drug is a cannabinoid-1 (CB1) receptor blocker. At this time there are no comparative studies comparing this new treatment with the currently available treatment options.
The costs of the available treatments are:
- Orlistat (Xenical®) - £39.51 per month
- Sibutramine (Reductil®) - £41.29 to £45.14 per month
- Rimonobant (Acomplia®) - £55.20 per month
Action: Based on the lack of comparative studies and the higher acquisition cost this drug provides a fourth-line choice in patients who fail to respond to diet and exercise followed by both existing treatment options.